Active, not recruiting
Not applicable
Endoscopic Mucosal Resection Versus Endoscopic Submucosal Dissection for Colorectal Laterally Spreading Lesions.
Condition(s) studied
Neoplasms, Colorectal
Investigational drug(s) / intervention(s)
Endoscopic mucosal resection (EMR)Endoscopic submucosal dissection (ESD)
Endoscopic mucosal resection (EMR): Endoscopic mucosal resection (EMR) is an endoscopic resection technique that allows the removal of large colorectal lesions using a conventional "lift-and-cut" procedure or an underwater technique
Endoscopic submucosal dissection (ESD): Endoscopic submucosal dissection (ESD) is an endoscopic procedure that allows dissection of larger colorectal lesions in one piece using endoknives.
The procedure is technically more difficult, much more time-consuming than EMR, mandates multiday hospital admission and has an increased risk of perforation.
Study summary
EMR and ESD are both effective and safe and are associated with a very low risk of procedure related mortality when performed for colorectal laterally spreading lesions (LSL).
Some kind of LSLs have a low risk of submucosal invasive carcinoma (SMIC) or these foci are found in well demarcated areas of the tumor. This is the case of the non-granular flat elevated (LSN-NG-FE) and the LSLs-G mixed subtypes.
The investigators aim to assess if piecemeal EMR (the older technique) for LSLs-G mixed type \> 30 mm and LSLs-NG FE type \> 20 mm is not inferior to ESD (the new treatment) for the need of additional surgery in the mid-term.
Eligibility
Inclusion Criteria:
* Adults (at least 18 years old).
* LSL-NG FE type ≥ 20mm or LST-G mixed type ≥30mm who have not been previously treated or received submucosal injection, regardless of their location in the colon.
* LSL-NG FE type ≥ 20mm or LST-G mixed type ≥30mm WITHOUT a demarcated area
* The patient must have undergone a complete colonoscopy, reaching the cecum, to detect possible synchronous lesion. If this procedure has not been done previously, it will be performed prior to the inclusion of the patient in the study.
* Patients able to fill in questionnaires written in Spanish or English.
Exclusion Criteria:
* Contra-indication to colonoscopy.
* Contra-indication to general anesthesia.
* Inability to stop antiplatelet agents and anti-coagulant according to the European Society of Gastro-Intestinal Endoscopy guidelines.
* Patients with \> 1 lesion meeting the inclusion criteria.
* LSL-NG FE type ≥ 20mm or LST-G ≥30mm mixed type that have been previously treated (Recurrence or residual lesion after previous endoscopic or surgical treatment).
* LSL-NG FE type ≥ 20mm or LST-G ≥30mm mixed type with previous submucosal injection, even if a resection attempt with a snare was not finally performed.
* Lesions with suspicion of deep submucosal invasive carcinoma: depression or invasive pit-pattern (Vi within a demarcated area or Vn).
* Submucosal mass like elevation within a LSL-NG FE type.
* LSLs having a previous biopsy or tattooing. Previous biopsies of the lesion should only be allowed if LSL-G mixed type \> 30 mm and samples were taken out of the flat area.
* LSL-G with a Buddha like deformation (Polyp on polyp)
* LSL involving a surgical anastomosis.
* LSL involving the appendicular orifice.
* LSL involving the terminal ileum.
* Patient's refusal to participate in the study
* Presence of inflammatory bowel disease
* Pregnant or lactating women.
* Hereditary colorectal cancer syndrome or hereditary polyposis.
* Patient under legal protection and or deprived of liberty by judicial or administrative decision.
* Patient already participating in an interventional clinical research protocol
* Patient who cannot be followed for the duration of the study.
* Inability to sign the informed consent of the study.
Primary outcome measure(s)
- Percentage of surgical referral after treatment — Month 18
Compare between two groups.
Trial sites (1)
| Facility | City | Region | Status |
|---|
| Hospital Universitario "12 de Octubre" |
Madrid |
Spain |
|
Other trials for the same condition
